Redeye provides a research update following the Q3 report published by Initiator Pharma earlier today. The report did not include any significant surprises as the company continues to operate at a low cash burn, showing promise for the financial runway ahead. With focus on business development efforts, we restate that the full priority for the immediate future will be to find a licensing partner for the candidate. We reiterate our fair value range with a base case valuation of SEK24.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/